% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Sponholz:275472,
      author       = {S. Sponholz and A. Koch and M. Mese and S. Becker and M.
                      Sebastian$^*$ and S. Fischer and S. Trainer and W.
                      Schreiner},
      title        = {{L}ung {C}ancer {R}esection after {I}mmunochemotherapy
                      {V}ersus {C}hemotherapy in {O}ligometastatic {N}onsmall
                      {C}ell {L}ung {C}ancer},
      journal      = {The thoracic and cardiovascular surgeon},
      volume       = {71},
      number       = {8},
      issn         = {0371-7364},
      address      = {Stuttgart},
      publisher    = {Thieme},
      reportid     = {DKFZ-2023-00782},
      pages        = {656-663},
      year         = {2023},
      note         = {2023 Dec;71(8):656-663},
      abstract     = {Background: Neoadjuvant immunochemotherapy is currently
                      being tested in pivotal trials for stage I to III nonsmall
                      cell lung cancer (NSCLC). The impact of immunochemotherapy
                      in patients with oligometastatic disease (OMD) remains
                      undefined. This study aimed to compare the outcomes of
                      radical treatment after the neoadjuvant course of
                      immunochemotherapy versus chemotherapy.Methods: We
                      retrospectively analyzed patients with OMD who were treated
                      with immunochemotherapy or chemotherapy combined with local
                      ablation of metastases and radical primary tumor resection
                      between 2017 and 2021. Group A included eight patients with
                      immunochemotherapy; Group B included seven patients with
                      chemotherapy. Descriptive statistical analysis included the
                      characteristics of the patients, tumors, and
                      outcomes.Results: There was no difference in postoperative
                      morbidity rates between the groups (p = 0.626). The
                      30-day mortality in both groups was $0\%.$ The median
                      overall survival for Group A was not reached, with a median
                      follow-up time of 25 (range: 13–35) months; the median
                      overall survival for Group B was 26 (range: 5–53) months.
                      In Group A, all patients remained alive; in contrast, in
                      Group B, four patients died (p = 0.026). There was no
                      local thoracic recurrence in either group. In Group B, the
                      recurrent disease was identified significantly more often
                      (12.5 vs. $85.75\%;$ p = 0.009). The rates of complete
                      and major pathologic response were 37.5 and $0\%$ in Group A
                      and 42.85 and $14.25\%$ in Group B, respectively.Conclusion:
                      Despite the small patient number and short-term results, the
                      progression-free and overall survival in patients with OMD
                      after local therapy for metastases and primary tumor
                      resection following a neoadjuvant course of
                      immunochemotherapy might be promising compared with
                      chemotherapy.},
      cin          = {FM01},
      ddc          = {610},
      cid          = {I:(DE-He78)FM01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36746400},
      doi          = {10.1055/a-2028-7955},
      url          = {https://inrepo02.dkfz.de/record/275472},
}